GlobeNewswire: Cannabis Science, Inc. Contains the last 10 of 106 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:41:27ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/08/11/2278450/0/en/UPDATE-Cannabis-Science-Inc-Successfully-Launches-its-CSI-Cannabis-Science-Coin-for-its-CSi-EDP-Utility-Project-Valuation-Tracking-https-cannabissciencecoin-com.html?f=22&fvtc=4&fvtv=42475UPDATE: Cannabis Science Inc., Successfully Launches its $CSI Cannabis Science Coin for its CSi-EDP Utility Project Valuation Tracking, https://cannabissciencecoin.com2021-08-11T04:00:00Z<![CDATA[All CSi-EDP Project Assignments Based on Project Valuations and $CSI Crypto Valuations]]>https://www.globenewswire.com/news-release/2021/08/10/2277942/0/en/Cannabis-Science-Inc-Successfully-Launches-its-CSI-Cannabis-Science-Coin-for-its-CSi-EDP-Utility-Project-Valuation-Tracking.html?f=22&fvtc=4&fvtv=42475Cannabis Science Inc., Successfully Launches its $CSI Cannabis Science Coin for its CSi-EDP Utility Project Valuation Tracking2021-08-10T12:10:38Z<![CDATA[https://cannabissciencecoin.com/ All CSi-EDP Project Assignments Based on Project Valuations and $CSI Crypto Valuations]]>https://www.globenewswire.com/news-release/2019/10/21/1932520/0/en/Cannabis-Science-Issues-2019-Guidance-Report-Under-SEC-Sanctions-the-Company-Goes-Private-as-It-Enters-Into-Step-2-of-Its-Growth-Transition-Enabling-Full-Transparency-and-Revenue-G.html?f=22&fvtc=4&fvtv=42475Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth2019-10-21T12:11:19Z<![CDATA[IRVINE, CA via NEWMEDIAWIRE, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has agreed to go private under sanctions by the U.S. Securities and Exchange Commission (“SEC”). All Cannabis Science shareholders and their shareholdings will remain intact under the same name and entity, Cannabis Science Inc., a Nevada Corporation. Cannabis Science shares will no longer be quoted or traded on any stock market exchange.]]>https://www.globenewswire.com/news-release/2019/09/06/1912114/0/en/Cannabis-Science-Enters-Transition-Stage-as-Trading-of-the-Company-s-Shares-is-Halted-The-Company-Will-Continue-to-Implement-Its-Growth-Strategy-and-Resolve-All-Outstanding-Fully-R.html?f=22&fvtc=4&fvtv=42475Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements2019-09-06T11:22:56Z<![CDATA[IRVINE, CA, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it is entering a transition stage as trading of the Company’s shares is halted. Cannabis Science will continue to implement its corporate growth strategy and intends to resolve all outstanding regulatory reporting and filing requirements as it goes through its transition.]]>https://www.globenewswire.com/news-release/2019/08/28/1907486/0/en/Cannabis-Science-Partners-With-CDN-Firm-NHS-Industries-to-Launch-the-CBIS-CDN-Economic-Development-Plan-CBIS-to-Use-Its-Relations-With-the-Harvard-International-Phytomedicines-and-.html?f=22&fvtc=4&fvtv=42475Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions 2019-08-28T04:30:00Z<![CDATA[IRVINE, CA, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has signed a joint venture agreement with a Canadian public company, NHS Industries, Ltd. NHS Industries (CSE: (NHS), (OTC: NNHHF)). The group will focus on job creation, deliver and develop public and private access educational content, and research various delivery platforms for medical cannabinoid-related products and services, all based on the CBIS Economic Development Plan for Canada, (CBIS/CDN EDP).]]>https://www.globenewswire.com/news-release/2019/08/15/1902713/0/en/Cannabis-Science-Prepares-Announcements-for-Revenues-and-Corporate-Growth-Finalizing-New-Asset-Partnerships-and-Acquisitions-Targeting-Positive-Cash-Flow-in-Key-Markets-Globally.html?f=22&fvtc=4&fvtv=42475Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally2019-08-15T17:30:31Z<![CDATA[IRVINE, CA, Aug. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is preparing to announce a number of exciting new partnerships and acquisitions as the Company prepares for a significant growth in revenue and positive cash flow from operations in key markets globally.]]>https://www.globenewswire.com/news-release/2019/08/05/1897137/0/en/Cannabis-Science-Successfully-Completes-European-Headquarters-and-Operations-Move-to-The-Netherlands-and-Completes-Shut-Down-of-All-Cannabis-Science-Europe-GmbH-Germany-Operations.html?f=22&fvtc=4&fvtv=42475Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations 2019-08-05T20:06:48Z<![CDATA[IRVINE, CA, Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has successfully completed reorganization of its European business to better align with the requirements of its customers, partners, and stakeholders. This move is expected to help improve the efficiency and effectiveness of CBIS’ European operations, and provide the necessary infrastructure to manage supply-chain logistics, new product development, and revenue growth. The Company’s activities, including cultivation, extraction, and manufacturing, will be headquartered in The Netherlands while all former Germany operations have been dissolved.]]>https://www.globenewswire.com/news-release/2019/07/26/1892443/0/en/Cannabis-Science-Inc-Successfully-Completes-Lab-Testing-for-Its-Proprietary-Short-Time-Vacuum-Distillation-Process-for-Distribution-of-Purified-High-CBDA-and-CBD-Water-Soluble-Powd.html?f=22&fvtc=4&fvtv=42475Cannabis Science, Inc. Successfully Completes Lab Testing for Its Proprietary, Short-Time Vacuum Distillation Process for Distribution of Purified High CBDA and CBD Water-Soluble Powders and Extracts Internationally2019-07-26T16:07:26Z<![CDATA[Laboratory Capacity Now Expands to Over 1,000 Kilograms Per Month of Purified High CBDA and CBD Water-Soluble Powders and Extracts for Full-Scale Product Development and Worldwide Wholesale Distribution]]>https://www.globenewswire.com/news-release/2019/07/08/1879373/0/en/Mr-Raymond-C-Dabney-Prepares-Cannabis-Science-for-the-Next-Level-With-Key-Acquisitions-Negotiated-and-Planned-Mergers-a-New-Branding-Splash-and-a-Black-Tie-Dinner-Awards-Gala-for-t.html?f=22&fvtc=4&fvtv=42475Mr. Raymond C. Dabney Prepares Cannabis Science for the Next Level With Key Acquisitions Negotiated and Planned Mergers, a New Branding Splash, and a Black-Tie Dinner Awards Gala for the Ages2019-07-08T11:34:04Z<![CDATA[Acquisitions Designed to Complete the Company’s Financials, Introduce New Branding, and Hold Its 2019 CBIS Awards Gala to Thank the Company’s Shareholders and Stakeholders]]>https://www.globenewswire.com/news-release/2019/06/03/1863214/0/en/Cannabis-Science-Propels-Cancer-Clinical-Trials-Appoints-Cellular-Cancer-Specialist-Dr-Sulma-Mohammed-Professor-of-Cancer-Biology-Purdue-University-to-the-Company-s-Scientific-Advi.html?f=22&fvtc=4&fvtv=42475Cannabis Science Propels Cancer Clinical Trials, Appoints Cellular Cancer Specialist Dr. Sulma Mohammed, Professor of Cancer Biology, Purdue University, to the Company’s Scientific Advisory Board2019-06-03T12:26:30Z<![CDATA[IRVINE, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the appointment of Dr. Sulma Mohammed, Professor of Cancer Biology at Purdue University, to the Company’s Scientific Advisory Board. Dr. Mohammed has extensive knowledge of molecular biology, cell biology, biochemistry, and microbiology, basic and applied medical sciences through her graduate programs at Cornell University and Purdue University, as well as experience in cancer research from the basic levels, to pre-clinical research in animal models, through to human clinical trials.]]>Dr. Sulma Mohammed, CBIS SAB Member Cannabis Science